Log in

Erytech Pharma Stock Price, News & Analysis (NASDAQ:ERYP)

$4.29
0.00 (0.00 %)
(As of 10/23/2019 08:00 AM ET)
Today's Range
$4.42
Now: $4.29
$4.42
50-Day Range
$4.02
MA: $4.77
$5.43
52-Week Range
$3.95
Now: $4.29
$10.65
Volume2 shs
Average Volume1,123 shs
Market Capitalization$76.96 million
P/E Ratio1.76
Dividend YieldN/A
Beta1.45
ERYTECH Pharma SA, a biopharmaceutical company, develops therapies for severe forms of cancer and orphan diseases. It is developing a pipeline of product candidates targeting solid and liquid tumors for patients with high unmet medical needs. The company's lead product candidate is eryaspase, which is used for the treatment of severe solid tumors, including pancreatic cancer and in acute lymphoblastic leukemia. Read More…

Industry, Sector and Symbol

Industry Biological products, except diagnostic
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:ERYP
CUSIPN/A
CIKN/A
Phone33-4-78-74-44-38

Debt

Price-To-Earnings

Sales & Book Value

Annual SalesN/A
Cash Flow$2.49 per share
Book Value$9.59 per share

Profitability

Miscellaneous

Employees172
Market Cap$76.96 million
Next Earnings DateN/A
OptionableNot Optionable

Receive ERYP News and Ratings via Email

Sign-up to receive the latest news and ratings for ERYP and its competitors with MarketBeat's FREE daily newsletter.


Erytech Pharma (NASDAQ:ERYP) Frequently Asked Questions

What is Erytech Pharma's stock symbol?

Erytech Pharma trades on the NASDAQ under the ticker symbol "ERYP."

What price target have analysts set for ERYP?

2 brokerages have issued 12-month price objectives for Erytech Pharma's stock. Their forecasts range from $13.00 to $13.00. On average, they expect Erytech Pharma's stock price to reach $13.00 in the next year. This suggests a possible upside of 203.0% from the stock's current price. View Analyst Price Targets for Erytech Pharma.

What is the consensus analysts' recommendation for Erytech Pharma?

2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Erytech Pharma in the last year. There are currently 2 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Erytech Pharma.

Has Erytech Pharma been receiving favorable news coverage?

Headlines about ERYP stock have been trending negative on Wednesday, InfoTrie Sentiment Analysis reports. The research group identifies negative and positive news coverage by reviewing more than six thousand news and blog sources in real time. The firm ranks coverage of companies on a scale of negative five to positive five, with scores nearest to five being the most favorable. Erytech Pharma earned a coverage optimism score of -2.5 on InfoTrie's scale. They also assigned media coverage about the company a news buzz of 10.0 out of 10, indicating that recent news coverage is extremely likely to have an effect on the stock's share price in the near future. View News Stories for Erytech Pharma.

Are investors shorting Erytech Pharma?

Erytech Pharma saw a increase in short interest during the month of September. As of September 30th, there was short interest totalling 1,100 shares, an increase of 37.5% from the August 30th total of 800 shares. Based on an average trading volume of 400 shares, the short-interest ratio is presently 2.8 days. Approximately 0.0% of the company's stock are sold short. View Erytech Pharma's Current Options Chain.

Who are some of Erytech Pharma's key competitors?

What other stocks do shareholders of Erytech Pharma own?

Who are Erytech Pharma's key executives?

Erytech Pharma's management team includes the folowing people:
  • Mr. Gil Beyen, Chairman & CEO (Age 57)
  • Mr. Jérôme Bailly Pharm.D., VP, Director of Pharmaceutical Operations & Deputy GM (Age 40)
  • Mr. Eric Soyer, CFO & COO (Age 53)
  • Dr. Alexander Scheer, Chief Scientific Officer (Age 57)
  • Naomi Eichenbaum, Director Investor Relations

When did Erytech Pharma IPO?

(ERYP) raised $125 million in an initial public offering (IPO) on Friday, November 10th 2017. The company issued 5,300,000 shares at a price of $23.00-$24.00 per share. Jefferies, Cowen and Oddo BHF served as the underwriters for the IPO and JMP Securities was co-manager.

How do I buy shares of Erytech Pharma?

Shares of ERYP can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

What is Erytech Pharma's stock price today?

One share of ERYP stock can currently be purchased for approximately $4.29.

How big of a company is Erytech Pharma?

Erytech Pharma has a market capitalization of $76.96 million. The company earns $-45,140,000.00 in net income (profit) each year or $2.44 on an earnings per share basis. Erytech Pharma employs 172 workers across the globe.View Additional Information About Erytech Pharma.

What is Erytech Pharma's official website?

The official website for Erytech Pharma is http://www.erytech.com/.

How can I contact Erytech Pharma?

Erytech Pharma's mailing address is 60 AVENUE ROCKEFELLER BATIMENT ADENINE, LYON I0, 69008. The company can be reached via phone at 33-4-78-74-44-38 or via email at [email protected]


MarketBeat Community Rating for Erytech Pharma (NASDAQ ERYP)

Community Ranking:  2.1 out of 5 (star star)
Outperform Votes:  136 (Vote Outperform)
Underperform Votes:  189 (Vote Underperform)
Total Votes:  325
MarketBeat's community ratings are surveys of what our community members think about Erytech Pharma and other stocks. Vote "Outperform" if you believe ERYP will outperform the S&P 500 over the long term. Vote "Underperform" if you believe ERYP will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 10/23/2019 by MarketBeat.com Staff

Featured Article: Straddles

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel